Compare Repligen Corporation Common Stock (RGEN) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vertiv Holdings Co — how do they compare? Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B), while Vertiv Holdings Co trades at $217.31 (market cap $91.35B). The key difference: Vertiv Holdings Co is far larger — about 8.2× Repligen Corporation Common Stock's market cap, and Vertiv Holdings Co pays a 0.11% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vertiv Holdings Co for 40 Days on average.
| RGEN | VRT | |
|---|---|---|
Market Cap | $11.14B | $91.35B |
Volume | 1,259,263 | 4,805,860 |
Sector | Health | Industrials |
52-Week High | $194.57 | $376.23 |
52-Week Low | $102.87 | $149.83 |
Typical Hold Time | 0 Days | 40 Days |
Enterprise Value | $11.02B | $91.58B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Vertiv (VRT) trades at $237.29, down 0.86% on the day, amid a bearish technical signal. The stock exhibits strong fundamentals with revenue growth from $10.23B in 2025 to $11.5B projected for 2026 and a robust net income margin of 15.09%. Recent earnings have consistently beaten estimates, and analyst sentiment remains overwhelmingly positive with a 90.48% buy rating and a consensus price target of $366.12. However, technical indicators show selling pressure, with the price near support at $237.
The outlook for VRT is favorable due to its strategic position in the AI data center infrastructure market, driving revenue and margin expansion. Key risks include execution of growth initiatives, competitive pressures, and market volatility. The significant upside to the analyst target presents a potential opportunity, but investors should weigh the strong fundamentals against the current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
